Aiping Zeng
Overview
Explore the profile of Aiping Zeng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
436
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao M, Hu X, Zhuang P, Zeng A, Yu Y, Chen Z, et al.
J Bone Oncol
. 2025 Feb;
51:100661.
PMID: 39995685
Introduction: Denosumab (Xgeva®) is a standard treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases (BM). This trial was designed to assess the equivalence of LY01011...
2.
He J, Liu Q, Zeng A, Ning R
Altern Ther Health Med
. 2024 Nov;
PMID: 39565699
Background: Thymic carcinoma is a rare and aggressive malignancy characterized by high invasiveness, poor prognosis, and limited treatment options post-chemotherapy failure. Anlotinib, a novel tyrosine kinase inhibitor, has shown promise...
3.
Zeng A, Gu Y, Ma L, Tao X, Gao L, Li J, et al.
Diagnostics (Basel)
. 2023 Dec;
13(24).
PMID: 38132262
This study aims to establish precise quality indicators for evaluating and enhancing ultrasound performance, employing a methodology based on a comprehensive review of the literature, expert insights, and practical application...
4.
Liu Q, Tan L, He J, Ning R, Zeng A, Chen Y
Int J Gen Med
. 2023 Nov;
16:5481-5491.
PMID: 38021044
Purpose: This study examined the association between plasma D-dimer levels and overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with osimertinib. Methods: In this multicenter study,...
5.
Shi Y, Qin X, Peng X, Zeng A, Li J, Chen C, et al.
Lancet Reg Health West Pac
. 2023 Mar;
31:100617.
PMID: 36879786
Background: KL-A167 is a fully humanized monoclonal antibody targeting programmed cell death-ligand 1. This phase 2 study aimed to evaluate the efficacy and safety of KL-A167 in Chinese patients with...
6.
Li H, Huang Y, Chen Z, Zeng A, Zhang H, Yu Y, et al.
BioDrugs
. 2023 Feb;
37(2):259-269.
PMID: 36802320
Background: Denosumab has been approved for the treatment of bone metastases from solid tumors. QL1206 is the first denosumab biosimilar and needs to be compared with denosumab in a phase...
7.
Chen S, Wei H, Zhao W, Jiang W, Ning R, Zhou S, et al.
Front Immunol
. 2022 Dec;
13:1059995.
PMID: 36569915
Background: The aim of this study was to assessment the efficacy and safety of Programmed cell death protein 1 (PD-1)/Programmed cell death-Ligand protein 1 (PD-L1) inhibitors plus anti-angiogenic agents with...
8.
Zhu H, Liu Z, Ma H, Zheng W, Liu J, Zhou Y, et al.
Insects
. 2022 Aug;
13(8).
PMID: 36005359
The diamondback moth () is one of the most destructive lepidopteran pests of cruciferous vegetables, and insights into regulation of its physiological processes contribute towards the development of new pesticides...
9.
Xiong A, Ren S, Liu H, Miao L, Wang L, Chen J, et al.
J Thorac Oncol
. 2022 Jul;
17(10):1216-1226.
PMID: 35798241
Introduction: As a novel third-generation EGFR tyrosine kinase inhibitor (TKI), SH-1028 (formerly oritinib) is developed to inhibit both sensitizing EGFR mutations and EGFR T790M mutation. Methods: This was a multicenter,...
10.
Liu J, Liu Z, Ma H, Yu Y, Zhang C, Zheng W, et al.
Insects
. 2022 Apr;
13(4).
PMID: 35447782
Trehalase regulates energy metabolism in insects by converting trehalose into two glucose molecules. High amounts of trehalase are critical for insect flight and larval stress resistance. However, whether trehalase participates...